In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species

J Infect Chemother. 2002 Mar;8(1):115-7. doi: 10.1007/s101560200019.

Abstract

The in-vitro activity of moxifloxacin, a new fluoroquinolone, against Chlamydia species was investigated. The minimal inhibitory concentration of moxifloxacin for 10 standard strains of different Chlamydia species and 15 wild-type strains of Chlamydia pneumoniae isolated in Japan, which were morphologically different from clinical isolates from the United States, ranged from 0.031 to 0.125 microg/ml. The activity of moxifloxacin was almost the same as those of sparfloxacin, and it was 16, 8, 2, and 2 times more active than ciprofloxacin, levofloxacin, grepafloxacin, and tosufloxacin, respectively. The minimal chlamydiacidal concentration of moxifloxacin ranged from 0.031 to 0.125 microg/ml. These results suggest that moxifloxacin has potential effects against Chlamydia species.

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Aza Compounds*
  • Chlamydia / drug effects*
  • Community-Acquired Infections / drug therapy
  • Fluoroquinolones*
  • Humans
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Pneumonia, Bacterial / drug therapy
  • Quinolines*

Substances

  • Anti-Infective Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Moxifloxacin